Kang, Keon Wook
M.D., Ph.D. / Professor
Molecular Imaging and Therapy Laboratory
TEL +82-2-2072-2803
FAX 02-745-7690
E-MAIL kangkw@snu.ac.kr
Research
Research Field
Major work of Laboratory of Molecular imaging and therapy is developing new agents or methods for visualizing or therapy of cancer.1. Developing new molecular imaging tools to visualize gene or protein expression (e.g. p53, HIF-1, hTERT and microRNAs, etc) using reporter genes such as sodium iodide symporter (NIS), fluorescence proteins, and luciferase for nuclear or bioluminescence imaging.
2. Developing molecular targeted imaging and treatment of tumor using multifunctional nanoparticles bioconjugated with albumin, antibodies, peptides, and aptamers.
3. In vivo cell trafficking of stem cells or immune cells using bioluminescence, fluorescence, radio-labeling, and MRI technology.
4. Developing new radiopharmaceuticals for cancer imaging or therapy using 99mTc, 18F, 11C, 124I, 68Ga, and etc.
5. Test of biodistribution, pharmacokinetics, and efficacy of new drug (including small molecules and bio-drugs) using in vivo imaging
https://www.youtube.com/watch?v=u6CI3OVn6dY
Keyword
Nuclear Medicine, Molecular Imaging, NanomedcineEducation
- 1985—1991 M.D. Seoul National University College of Medicine
- 1999—2001 Ph.D. in Medicine, Seoul National University Graduate School
Career
- 2000—2006 Chief, Department of Nuclear Medicine, Hospital, National Cancer Center, Korea
- 2003—2004 Visiting Scientist, Molecular Imaging Program at Stanford University, Stanford, CA, U.S.A.
- 2007—present. Professor, Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea
- 2013—2021 Member, Committee 3 (Medicine), International Commission on Radiological Protection
- 2019—present. Vice Director, Bio-MAX Institute, Seoul National University, Seoul, Korea
- 2020—present. Director, Translational Research Institute, Biomedical Research Institute, Seoul National University Hospital
- 2020—present. President Elect, the Korean Society of Nuclear Medicine
- 2021—present. Board Member, World Molecular Imaging Society
Publication
- Park CR, Kim HY, Song MG, Lee YS, Youn H, Chung JK, Cheon GJ, Kang KW. Efficacy and Safety of Human Serum Albumin-Cisplatin Complex in U87MG Xenograft Mouse Models. Int J Mol Sci. 2020 Oct 26;21(21):7932.
- Park CR, Song MG, Park JY, Youn H, Chung JK, Jeong JM, Lee YS, Cheon GJ, Kang KW. Conjugation of arginylglycylaspartic acid to human serum albumin decreases the tumor-targeting effect of albumin by hindering its secreted protein acidic and rich in cysteine-mediated accumulation in tumors. Am J Transl Res. 2020 Jun 15;12(6):2488-2498.
- Park CR, Jo JH, Song MG, Park JY, Kim YH, Youn H, Paek SH, Chung JK, Jeong JM, Lee YS, Kang KW. Secreted protein acidic and rich in cysteine mediates active targeting of human serum albumin in U87MG xenograft mouse models. Theranostics. 2019 Oct 11;9(24):7447-7457.
- Park JY, Song MG, Kim WH, Kim KW, Lodhi NA, Choi JY, Kim YJ, Kim JY, Chung H, Oh C, Lee YS, Kang KW, Im HJ, Seok SH, Lee DS, Kim EE, Jeong JM. Versatile and Finely Tuned Albumin Nanoplatform based on Click Chemistry. Theranostics. 2019 May 18;9(12):3398-3409.
- Lodhi NA, Park JY, Kim K, Kim YJ, Shin JH, Lee YS, Im HJ, Jeong JM, Khalid M, Cheon GJ, Lee DS, Kang KW. Development of 99mTc-Labeled Human Serum Albumin with Prolonged Circulation by Chelate-then-Click Approach: A Potential Blood Pool Imaging Agent. Mol Pharm. 2019 Apr 1;16(4):1586-1595.
